Cargando…

Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy

High intracellular reactive oxygen species (ROS) level is characteristic of cancer cells and could act as a target for the efficient targeted drug delivery for cancer treatment. Consequently, biomaterials that react to excessive levels of ROS are essential for biomedical applications. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Yaqin, Zhang, Wei, Fan, Guorun, Zou, Chenming, Zhang, Jie, Wu, Nan, Ding, Jiahui, Zou, Wen Qing, Xiao, Hongjun, Tan, Songwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026753/
https://www.ncbi.nlm.nih.gov/pubmed/36916054
http://dx.doi.org/10.1080/10717544.2023.2189106
_version_ 1784909580217614336
author Tu, Yaqin
Zhang, Wei
Fan, Guorun
Zou, Chenming
Zhang, Jie
Wu, Nan
Ding, Jiahui
Zou, Wen Qing
Xiao, Hongjun
Tan, Songwei
author_facet Tu, Yaqin
Zhang, Wei
Fan, Guorun
Zou, Chenming
Zhang, Jie
Wu, Nan
Ding, Jiahui
Zou, Wen Qing
Xiao, Hongjun
Tan, Songwei
author_sort Tu, Yaqin
collection PubMed
description High intracellular reactive oxygen species (ROS) level is characteristic of cancer cells and could act as a target for the efficient targeted drug delivery for cancer treatment. Consequently, biomaterials that react to excessive levels of ROS are essential for biomedical applications. In this study, a novel ROS-responsive polymer based on D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) and poly (β-thioester) (TPGS-PBTE) was synthesized for targeted delivery of the first-line antineoplastic drug, paclitaxel (PTX). The resultant TPGS-PBTE NPs showed good ROS-responsive capability in size change and drug release. Compared to PTX, PTX-loaded nanoparticles (PTX@TPGS-PBTE NPs) showed enhanced cytotoxicity and higher level of apoptosis toward squamous cell carcinoma (SCC-7) cells. Tumor-targeted delivery of the NPs was also observed, especially after being modified with a tumor-targeting peptide, cRGD. Enhanced tumor growth inhibition was also observed in head and neck cancer SCC-7 murine models. In summary, PTX@TPGS-PBTE NPs can achieve good therapeutic effects of PTX against head and neck cancer both in vitro and in vivo, especially when modified by cRGD for active targeting, which enriched the application of ROS responsive system utilized in the delivery of anticancer drugs.
format Online
Article
Text
id pubmed-10026753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100267532023-03-21 Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy Tu, Yaqin Zhang, Wei Fan, Guorun Zou, Chenming Zhang, Jie Wu, Nan Ding, Jiahui Zou, Wen Qing Xiao, Hongjun Tan, Songwei Drug Deliv Research Article High intracellular reactive oxygen species (ROS) level is characteristic of cancer cells and could act as a target for the efficient targeted drug delivery for cancer treatment. Consequently, biomaterials that react to excessive levels of ROS are essential for biomedical applications. In this study, a novel ROS-responsive polymer based on D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) and poly (β-thioester) (TPGS-PBTE) was synthesized for targeted delivery of the first-line antineoplastic drug, paclitaxel (PTX). The resultant TPGS-PBTE NPs showed good ROS-responsive capability in size change and drug release. Compared to PTX, PTX-loaded nanoparticles (PTX@TPGS-PBTE NPs) showed enhanced cytotoxicity and higher level of apoptosis toward squamous cell carcinoma (SCC-7) cells. Tumor-targeted delivery of the NPs was also observed, especially after being modified with a tumor-targeting peptide, cRGD. Enhanced tumor growth inhibition was also observed in head and neck cancer SCC-7 murine models. In summary, PTX@TPGS-PBTE NPs can achieve good therapeutic effects of PTX against head and neck cancer both in vitro and in vivo, especially when modified by cRGD for active targeting, which enriched the application of ROS responsive system utilized in the delivery of anticancer drugs. Taylor & Francis 2023-03-14 /pmc/articles/PMC10026753/ /pubmed/36916054 http://dx.doi.org/10.1080/10717544.2023.2189106 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Article
Tu, Yaqin
Zhang, Wei
Fan, Guorun
Zou, Chenming
Zhang, Jie
Wu, Nan
Ding, Jiahui
Zou, Wen Qing
Xiao, Hongjun
Tan, Songwei
Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title_full Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title_fullStr Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title_full_unstemmed Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title_short Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
title_sort paclitaxel-loaded ros-responsive nanoparticles for head and neck cancer therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026753/
https://www.ncbi.nlm.nih.gov/pubmed/36916054
http://dx.doi.org/10.1080/10717544.2023.2189106
work_keys_str_mv AT tuyaqin paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT zhangwei paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT fanguorun paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT zouchenming paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT zhangjie paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT wunan paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT dingjiahui paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT zouwenqing paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT xiaohongjun paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy
AT tansongwei paclitaxelloadedrosresponsivenanoparticlesforheadandneckcancertherapy